Prognostic value of selected immunohistochemical markers in skin melanoma by Kycler, W. et al.
NOWOTWORY Journal of Oncology • 2002 • volume 52
Number 6• 487–495
Prognostic value of selected immunohistochemical markers in skin melanoma
Witold Kycler1, Sylwia Grodecka-Gazdecka2, Jan Br´borowicz2, 
Violetta Filas2, Marek Teresiak1
A i m:  to assess the significance of the expression of metalloproteinase 2 (MMP-2), CD44 glycoprotein and nm23 diphospha-
te nucleoside kinase on melanoma progression and survival time and its comparison with the influence of clinical and histo-
pathological parameters.
M a t e r i a l  a n d  m e t o d s:  39 patients operated for the first time because of melanoma in the 2nd Department of Oncolo-
gical Surgery of the Greatpoland Cancer Centre in Poznan between the years 1990-1994.
Clinical data such as age, gender, the occurrence of cancer spread, its location and survival time were assessed.
Using archival histopathological specimens we assessed the thickness of tumour invasion in mm according to Breslow, the le-
vel of invasion according to Clark, histological type, the presence of lymphocyte infiltration, regression symptoms, the existen-
ce of preexisting naevus, the presence of ulceration, the presence of satellites and metastases to lymphatic nodes.
Immunohistochemical marker expression was performed in tissue material obtained from archival paraffin blocks. The
presence of HMB-45 and PCNA, the expression of metalloproteinase 2 (MMP-2), CD44 glycoprotein and nm23 diphospha-
te nucleoside kinase were also assessed. Clinical, histopathological and immunohistochemical data was analysed in correla-
tion with survival time. The evaluation of prognostic factors was performed by Cox’s nonparametric proportional hazard re-
gression model.
R e s u l t s:  the crucial prognostic factor in the examined group turned out to be the presence of a positive reaction product at
the site of nm23 diphosphate nucleoside kinase existence in correlation with both clinical and histological factors. In the grow-
up of pathological factors the prognostic significance of the lymphatic metastases at the onset of treatment was demonstrated.
C o n c l u s i o n s:  the results indicate that the greatest prognostic value of skin melanoma progression lies in the demonstra-
tion of nm23 diphosphate nucleoside kinase in skin.
Markery immunohistochemiczne w czerniaku
C e l  p r a c y.  Celem pracy jest ocena znaczenia metaloproteinazy 2 (MMP-2), glikoproteiny CD44 i nm23 kinazy dwufosfo-
nukleozydowej dla przebiegu czerniaka skóry w porównaniu z wp∏ywem czynników klinicznych i histopatologicznych na
czas prze˝ycia.
M a t e r i a ∏  i m e t o d y k a.  Analizowano dane 39 pacjentów operowanych z powodu czerniaka w Wielkopolskim Centrum
Onkologii w Poznaniu w II Oddziale Chirurgii Onkologicznej po raz pierwszy w latach 1990-1994. Ocenie poddano dane kli-
niczne, takie jak: wiek, p∏eç, pojawienie si´ rozsiewu nowotworowego, jego lokalizacj´ oraz czas prze˝ycia.
Na podstawie archiwalnych preparatów histopatologicznych oceniono: gruboÊç nacieku guza w mm wg Breslow'a, poziom na-
ciekania wg Clarka, postaç histologicznà, obecnoÊç nacieku limfocytarnego, cechy regresji, obecnoÊç owrzodzenia, obecnoÊç
satelitów i przerzutów do w´z∏ów ch∏onnych. Przeprowadzono badania ekspresji markerów immunohistochemicznych w ma-
teriale tkankowym uzyskanym z archiwalnych bloczków parafinowych. OkreÊlono obecnoÊç HMB-45 i PCNA, ekspresj´ me-
taloproteinazy 2 (MMP-2), glikoproteiny CD44 i nm23 kinazy dwufosfonukleozydowej. Dane kliniczne, histopatologiczne i im-
munohistochemiczne oceniono w korelacji z czasem prze˝ycia. Ocen´ czynników prognostycznych przeprowadzono metodà
nieparametrycznego modelu proporcjonalnego hazardu wg Coxa.
W y n i k i.  Najistotniejszym czynnikiem rokowniczym w badanej grupie okaza∏ si´ dodatni wynik reakcji na obecnoÊç nm23
kinazy dwufosfonukleotyzydowej i to zarówno w korelacji z czynnikami klinicznymi jak i histopatologicznymi. SpoÊród
czynników patoklinicznych stwierdzono znaczenie rokownicze obecnoÊci przerzutów w w´z∏ach ch∏onnych w chwili rozpocz´-
cia leczenia.
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Introduction
The clinical diagnosis of melanocytic lesions suspected
of skin melanoma usually arises from a change in the
appearance of skin lesion on the basis of characteristic
symptoms classified in two systems: ABCD and the 7-
-point Glasgow scale. Some lesions with no clear-cut clini-
cal diagnosis can be qualified for excision biopsy leaving
a healthy skin margin, also broadened by a suitable frag-
ment of subcutaneous lipid tissue to perform an exact
histological assessment [1].
Morphological details of melanoma also allow for
a preliminary assessment of progression and for establi-
shing a treatment course.
Typical histological prognostic factors are: the thick-
ness of melanoma measured by Breslow method in mm
[2], the status of regional lymphathic nodes [3-6], the level
of invasion measured according to Clark [2-7], histolo-
gical type of Superficial Spreading Melanoma Malignum
(SSMM) [7-11] (with better prognosis), ulceration and
vessel invasion (which are closely related to tumour inva-
sion level and do not remain independent prognostic fac-
tors) [9], and lymphocyte infiltration (examined by Cle-
mente et al.) [5].
The most frequently considered clinical parameters
are: age (Balzi et al. [8] estimated the age above 60 to ha-
ve a better prognosis; according to Kuno et al. the limit is
the age of 70 [12]), male sex and tumour location on the
trunk, shoulder girdle, neck or head [5, 8, 10, 13].
The only independent prognostic factors according
to many authors [3, 7, 9, 11] are lesion thickness, the exi-
stence of lymphatic metastases detected at the beginning
of treatment and the degree of clinical advance estimated
on that basis.
The search for, and assessment of, more prognostic
factors is indispensable to improve the results of treat-
ment.
The most frequently assessed immunohistochemical
markers are: S-100 protein, HMB-45, vimentin, tirosina-
se (TRP-1) and proliferative factors such as p53 protein,
Ki-67 (MIB1) and PCNA. According to the results of
Niezabitowski et al. another independent prognostic fac-
tor was proliferative antigen expression (PCNA and Ki 67
[5]). Other authors emphasize the importance of PCNA
and Ki67 in the differentiation of melanoma cells, its pro-
liferative abilities and indirect influence on tumour in-
vasion level, however they do not always confirm their
correlation with survival probability [14-16]. Karbowni-
czek et al. [14] have described an association between
the area and shape of melanoma cell nuclei (with positive
results for Ki67) and the presence of metastases, and
between the nuclear area and of tumour cells and such
factors related to poor prognosis as the depth of inva-
sion and tumour thickness. Talve et al. [15] have stres-
sed the importance of proliferative parameters such as
Ki67 and mitotic index, however they did not prove their
influence on the predicted survival rate. Rudolph et al.
[16] have proven the value of Ki67 for the diagnosis and
differentiation of benign melanocytic changes from mela-
noma. Other markers, such as HMB-45, S-100, vimen-
tin and tirosinase, have been applied in the diagnosis and
differentiation research but did not display any prognostic
value.
However a group of new melanoma markers inclu-
ding metalloproteinase-2 (MMP-2), CD44 glycoprotein
and nm23 diphosphate nucleoside kinase has been di-
scerned.
Metalloproteinases (MMP) are a group of enzymes
responsible for rebuilding structural proteins of extracel-
lular spaces and basement membrane. MMP consists of
17 enzymes belonging to different groups (collagenase,
gelatinase, stromatin enzyme, membrane MMP and
others). They take part in connective tissue transforma-
tions, stimulation of plate aggregation (regardless of A2
thromboxane), the process of wound healing, angioge-
nesis, the process of adhesion and cell migration thro-
ugh biological membranes. First of all MMP's are pro-
duced by monocytes, macrophages and granulocytes.
They are also involved in tumor metabolism and are se-
creted by adenocarcinoma cells of the digestive tract, bre-
ast, stomach, liver, colon, prostate, ovary and cystic urina-
ry cancers. The increase of MMP level is also related to
the direct damage of tissue structure which causes the
activation of the physiological regeneration processes,
that is why MMP level is increased in inflammatory con-
ditions, for example in osteoporosis, rheumatoid arthritis,
chronic lung disease, hepatitis etc. Metalloproteinases
are one of the elements of melanoma metabolism and
they also have some influence on its growth, invasion and
metastatic potential. Their activity on invasive melanoma
cells along with the presence of superficial glycoprotein
CD44 and integrin alphavbeta3 [17 18] was confirmed.
In 1985 Väisänen et al. provided the first publication con-
cerning the influence of collagenase IV, belonging to the
group of gelatinases (gelatinase A, MMP-2), on the cour-
se of melanoma [19]. In this and in a number of further
papers the importance of MMP-2 as a prognostic parame-
ter of melanoma was proven [19, 20]. Direct significance
of MMP-2 for tumour cell metabolism is based on incre-
asing the abilities of biological membranes invasion and
changing adhesive abilities, which makes them capable
of migration and colonization, thus forming distant meta-
stases. Direct connection was found between MMP-2 and
the increased risk of distant metastases by blood and it
Wnioski. Przeprowadzone badanie wykaza∏o w badanej grupie chorych przydatnoÊç oznaczania nm23 kinazy dwufosfonukle-
ozydowej w prognozowaniu przebiegu czerniaka skóry.
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was shown to be a prognostic factor of survival time, re-
gardless of the thickness of invasion according to Bre-
slow and the level of invasion according to Clark. MMP-
-2 expression was related to the level of clinical advance-
ment and patient gender. The higher survival rate in
women than in men still remains unexplained. The con-
nection between metastases occurring in women with bre-
ast cancer and hormonal activity was indicated. Oestro-
gens are influencing the regulation of collagen IV secre-
tion, which reduces breast cancer cell activity. This leads
to a reduction of metalloproteinase secretion (gelatinase
B). According to Väisänen et al. there may also exist an
influence of oestrogens on MMP-2 decreasing the risk
of melanoma metastases by blood in women [19].
The prognostic value of proteolytic enzymes in mela-
noma was also studied by Otto et al. [21]. Differences in
the occurrence of MMP-2 in patients suffering from me-
lanoma with and without metastases were shown. More-
over, the significant prognostic parameters in the above-
-mentioned study were: positive reaction to the appe-
arance of catepsine B and D, gender, lesion location,
tumour thickness according to Breslow, the level of inva-
sion according to Clark and the presence of ulceration.
During the research on melanoma immunohistoche-
mical markers we also studied the elements of protein
and receptor structure of melanoma cells and connective
tissue, which come into contact with each other during mi-
gration and metastases formation. Significance is attri-
buted to superficial CD44 receptors responsible for inter-
cellular adhesion and for adhesion between melanoma
cells and structural connective tissue (matrix) [22, 23]. It
has been proven that CD44 glycoprotein expression on
the surface of melanoma cells increases migration and
invasion ability contributing to the increased risk of meta-
stases and melanoma progression [22]. Thomas et al. [24],
Goebeler et al. [25], Maaser et al. [26] and other authors
[27, 28] have demonstrated increased migration ability
in melanoma cells with the presence of antigen CD44 in
an environment of hyaluronic acid. Takahashi et al. [29]
has shown the connection of CD44 expression with MMP-
-2 in melanoma cells metabolism.
Numerous proteins are responsible for the complex
process of melanoma metabolism, their expression is con-
trolled by genes. One of the earlier studied suppressor
genes located on the 17q chromosome is a gene responsi-
ble for nm23 diphosphate nucleoside kinase production.
The assessment of this protein expression proved inhibi-
tion of melanoma progression [30-34]. Lee et al. [30],
Betke et al. [31], Florens et al. [32] confirmed the signifi-
cance of nm23 as a prognostic factor. Nm23 protein influ-
ences the degree of tumour differentiation and its prolife-
rative abilities. However not all authors confirm its corre-
lation with the formation of remote metastases and direct
influence on survival time [34-38].
Malignant melanoma has a high malignancy and
a surprising disease progression is sometimes noticed.
Therefore much research goes on to attempt to explain
this problem. The existence of numerous melanoma cell
lines makes it difficult to search for universal and repeata-
ble markers and prognostic factors. The assessment of
an greater number of prognostic factors may make it
easier to establish new standards of melanoma treatment.
The aim of the study
The aim of this study was to assess the significance of
metalloproteinase 2 (MMP-2), CD44 glycoprotein and
nm23 diphosphate nucleoside kinase on melanoma
progression and survival time, as compared to the in-
fluence of clinical and histopathological parameters.
Material and methods
The clinical, histopathological and immunohistochemical data is
presented in Tables I – III. We have performed an analysis of
39 patients operated for the first time for melanoma at the Gre-
atpoland Cancer Centre between the years 1990-1994. Clinical
data such as age, gender, the occurrence of tumor spread, its lo-
cation and survival time were assessed. Histological assessment
was performed on archival routine hematoxyline/eosin – sta-
ined histopathological specimens which were described in terms
of the thickness of melanoma infiltration in mm acc. to Bre-
slow, the level of invasion acc. to Clark, histological type, the pre-
sence of lymphocyte infiltration, regression features, the exi-
stence of a pre-existing naevus, the presence of ulceration and
the the existence of satellites and lymphatic metastases.
Table I. Clinical characteristics of patients
Characteristic No Percentage
Number of patients 39 100 %
Mean age, range 51,35 (27-79)
Sex male 9 23.07 %
female 30 76.92 %
Five year surviving 24 61.54 %
Dissemination 18 46.15 %
Site of
metastases lymph node 15 38.46 %
skin 8 20.51 %
internal organs 12 30.76 %
Lesion
location trunk, shoulder girdle,
neck or head 17 43.58 %
limbs 22 56.41 %
Range of first operation
Lymphadenectomy carried out along
with tumor excision 17 47.22 %
Tumour excision 19 52.78 %
Tests for immunohistochemical marker expression were
performed on the material received from archival paraffin blocks
containing tumor tissue, which had been 10% formalin fixed
and embedded according to typical histological methods. 4-5µm
sections were prepared. Amplification of reaction products was
performed using the En Vision + TM /HRP (Mouse and Rabbit)
complex. The presence of HMB-45 and PCNA was determi-
ned. The expression of metalloproteinase 2 (MMP-2), CD44
glycoprotein and nm23 diphosphate nucleoside kinase from the
group of lastest melanoma markers was examined. Positive and
negative results of staining were analysed.
Survival analysis was performed using the Kaplan-Meier
method. Statistical significance of prognostic factors depending
on survival time was assessed by Cox nonparametric proportio-
nal hazard regression model.
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Results
The average age of the patients in the examined group
was 51,3 years old (27-79 years + 13.11 SD). The group
consisted of 30 women (76.9%) and 9 men (23.1%). 24
patients (61.5%) survived over 5 years. Lesions originating
from the trunk, head, neck, shoulder girdle were found in
17 patients (43.6%) and from the limbs in 22 patients
(56.4%). Melanoma spread during observation was detec-
ted in 18 patients (46.2%). Metastases were most frequent
in the lymphatic nodes – 15 cases (38.5%), in internal or-
gans – 12 cases (30.8%) and in the skin – 8 cases (20.5%).
As to the thickness of lesions according to Breslow, 6 pa-
tients (15.3%) had a Breslow score <0.75 mm; 10 pa-
tients (25.6%) – 0.76-1,5 mm; 8 patients (20.5%) – 1.51-
-4.0 mm; 15 patients (38.6%) ->4mm. Level II invasion
according to Clark was found in 7 patients (17.9%), level
III in 17 (43.6%), level IV in 12 (30.8%) and level V in 3
(7.7%). In the examined group of patients regional lym-
phatic metastases were found in 15 patients at the be-
ginning of treatment. Superficial forms of SSMM type
melanoma were found in 35 patients (87.2%), and of tu-
mour type – in 5 patients (12.8%). Ulceration was found
in 19 patients (48,7%). Regression symptoms were fo-
und in 19 patients. Lymphocyte infiltration occurred in 23
patients (58.97%). The existence of a preexisting naevus
was found in 7 patients (17.9%). Amelanotic type melano-
mas were present in 12.82% of the examined group (5 pa-
tients). No satellite changes were found in the examined
patients.
Suitable specimens for immunohistochemical stu-
dies were unavailable in 3 cases. Those 3 patients were
excluded from further statistical analysis.
In some cases it was difficult to assess the expres-
sion of nm23, CD44 and MMP-2 owing to the presence of
excess melanin, which masked immunohistological reac-
tions. The interpretation of the results was based on com-
parison with hematoxyline/eosin-stained specimens.
We did not manage to assess markers for nm23 di-
phosphate nucleoside kinase in 5 patients (13.9%), for
glycoproteinase CD44 in 3 cases (8.3%) and for metallo-
proteinase 2 (MMP-2) in 1 case (2.8%). PCNA and
HMB-45 were marked in all cases.
The HMB-45 marker reacted positively in 36 pa-
tients (100%). PCNA marker reacted positively in 24 pa-
tients (66.7%) and negative reactions were observed in 12
(33.3%). MMP-2 expression was detected in 13 patients
(36.1%) and negative reactions were observed in 22
(61.1%). Nm23 diphosphate nucleoside kinase was de-
tected in 20 patients (55.6%) and negative reactions were
observed in 11 (30.5%). The existence of CD44 glyco-
protein receptors was reported in 20 patients (55.6%)
and negative reactions were seen in 13 (36.1%). Positive
reactions to the existence of immunohistochemical mar-
kers mentioned above are presented in Fig. 1-5.
The median survival time according to the Kaplan-
-Meier method was 86,4 months, lower quartile (25th
percentile) was 28 months. The curve of survival func-
tion is presented in Fig. 6.
Statistical significance of the examined prognostic
factors was assessed using Cox's proportional hazards re-
gression model of survival.
Due to the lack of satellite changes and 100% positi-
ve reaction to HMB-45 antigen existence these indica-
tors were excluded from statistical analysis in the exami-
ned patients.
The following parameters were analysed: age, gen-
der, lesion location, the range of surgery (lymphadenecto-
my carried out along with tumour excision), the depth of
invasion in mm according to Breslow, the level of invasion
according to Clark, the existence of lymphatic metastases,
histological type of SSMM, ulceration, regression fac-
tors, the presence of a preexisting naevus, the presence of
Table II. Histological characteristics of tumor data
Characteristic No Percentage
Histology type SSMM 34 87.18 %
NMM 5 12.82 %
Thickness 0 – 0.75 6 15.38 %
according to 0.76 – 1.5 10 25.64 %
Breslow 1.51 – 4.0 8 20.51 %
>4.0 15 38.56 %
Level I
of invasion II 7 17.95 %
according to III 17 43.58 %
Clark IV 12 30.76 %
V 3 7.69 %
Metastases to lymph nodes 15 38.46 %
Lymphocyte yes 23 58.97 %
infiltration no 16 41.03 %
Regression yes 19 48.71 %
symptoms no 20 51.29 %
Presence of yes 19 48.71 %
ulceration no 20 51.29 %
Satellites yes 0 0
no 39 100 %
Preexisting naevus 7 17.94 %
Melanin yes 34 87.18 %
pigment no 5 12.82 %
Table III. Immunohistochemical data
Immunohistochemical factor No Percentage
HMB45 positive 36 100 %
negative 0 0 %
no result 0 0 %
PCNA positive 24 66.7 %
negative 12 33.3 %
no result 0 0 %
nm23 positive 20 55.6 %
negative 11 30.5 %
no result 5 13.9 %
MMP-2 positive 13 36.1 %
negative 22 61.1 %
no result 1 2.8 %
CD44 positive 20 55.6 %
negative 13 36.1 %
no result 3 8.3 %
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melanin, positive reaction to PCNA, metalloproteinase 2
(MMP-2), CD44 glycoprotein and nm23 diphosphate nuc-
leoside kinase.
The results are presented in Tables IV – VI.
Within the group of clinical and immunohistoche-
mical factors the expression of nm23 diphosphate nuc-
leoside kinase showed statistical correlation with survival
time (p=0.0202).
Figure 5. Positive staining: CD44 (400x)
Figure 4. Positive staining: MMP-2 (400x)Figure 3. Positive staining: nm23 (400x)
Figure 2. Positive staining PCNA (400x)Figure 1. Positive staining: HMB-45 (400x)
Figure 6. Graph of survival times vs. cumulative proportion surviving
according to the Kaplan-Meier method.
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Table IV. Statistical significance of clinical and immunohistochemical factors affecting survival time, 
assessed by Cox nonparametric proportional hazard regression model
Statistical survival analysis Depended variable: survival – (months)
Censoring observationes – 18
df = 8; p = 0.019 (p<0.05)
Prognostic factor n Category Relative risk (Exponent beta) p
Age 36 continuous variable 1.0009 p=0.9641
Gender 30 female 1.56 p=0.5247
9 male 0.64 p=0.5247
Limb location 22 2.61 p=0.7718
Lymphadenectomy 17 0.58 p=0.3222
PCNA 24 positive staining 2.26 p=0.6154
nm23 20 positive staining 0.08 p=0.0202
MMP-2 13 positive staining 0.81 p=0.4984
CD44 20 positive staining 0.44 p=0.3503
Table V. Statistical significance of histopathological and immunohistochemical factors affecting survival time, 
assessed by Cox nonparametric proportional hazard regression model
Statistical survival analysis Depended variable: survival – (months)
Censoring observationes – 18
df = 13; p = 0.0094 (p<0.05)
Prognostic factor n Category Relative risk (Exponent beta) p
Lymph node metastases 15 3.77 p=0.1411
Breslow thickness 36 continuous variable 0.91 p=0.2366
Clark level 36 0.76 p=0.2856
SSMM type 34 0.47 p=0.4451
Ulceration 19 4.50 p=0.5666
Lymphocyte infiltration 23 1.38 p=0.7012
Regression symptoms 19 0.37 p=0.6919
Preexisting naevus 7 5.60 p=0.1218
Melanin pigment 34 1.28 p=0.7484
PCNA 24 positive staining 2.50 p=0.4702
nm23 20 positive staining 0.057 p=0.0452
MMP-2 13 positive staining 1.06 p=0.6191
CD44 20 positive staining 0.33 p=0.3833
Table VI. Statistical significance of histopathological factors affecting survival time,
assessed by Cox nonparametric proportional hazard regression model
Statistical survival analysis Depended variable: survival – (months)
Censoring observationes – 18
df = 9; p = 0.024 (p<0.05)
Prognostic factor n Category Relative risk (Exponent beta) p
Lymph node metastases 15 4.36 p=0.0175
Breslow thickness 36 continuous variable 3.51 p=0.0543
Clark level 36 0.37 p=0.1912
SSMM type 34 0.65 p=0.6598
Ulceration 19 1.09 p=0.9184
Lymphocyte infiltration 23 0.36 p=0.2267
Regression symptoms 19 0.96 p=0.9771
Preexisting naevus 7 1.90 p=0.4101
Melanin pigment 34 1.02 p=0.9788
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The comparison of survival functions of a group of
patients showing positive reaction to the existence of
nm23 protein with a group of negative result according to
the Kaplan – Meier method is presented in Fig. 7. No
statistical correlation was found in the examined group
between nm23 expression and the occurrence of distant
metastases (Chi-square=2.78; p=0.95).
The remaining parameters such as: age, gender,
lesion location, lymphadenectomy carried out along with
tumour excision, positive reaction to PCNA, metallopro-
teinase 2 (MMP-2) and CD44 glycoprotein did not display
statistically significant influence on the survival of exa-
mined patients. In the group of histopathological factors
in comparison with immunohistochemical markers a po-
sitive result of the reaction to nm23 diphosphate nucleosi-
de kinase presence (p=0.0452) displayed a statistically
significant correlation with survival. Other factors such as:
the thickness of lesion according to Breslow, the presen-
ce of lymphatic metastases at the beginning of treatment,
the level of invasion according to Clark, histological type
SSMM, the presence of ulceration, regression symptoms,
preexisting naevus, melanin, positive reaction to PCNA,
metalloproteinase 2 (MMP-2) and CD44 glycoprotein
did not show any statistically significant influence on the
patients survival.
Statistical analysis performed in order to assess the
relationship between histopathological factors and survi-
val time showed statistically significant influence on the
existence of melanoma metastases in regional lymphatic
nodes at the beginning of treatment for patients in whom
lymphadenectomy was carried out along with tumor exci-
sion (p=0.0175).
Comments and discussion
The results show that 25% patients died within 28 months
and 50% lived longer than 86.4 months. 61.5% patients
survived 5-years or more. The ability to determine the
group of patients with increased risk of disease progres-
sion is an important element in treatment planning.
The crucial prognostic factor in the examined group
turned out to be a positive reaction result to nm23 di-
phosphate nucleoside kinase both in correlation with cli-
nical and histological factors. Its importance is emphasi-
zed by many authors. Betke et al. performed an asses-
sment of the presence of nm23 protein in benign naevi,
malignant melanomas and melanoma metastases to lym-
phatic nodes and internal organs [31]. They found that in
the group of patients they examined reduced nm23
expression is correlates significantly with survival time
and with the presence of metastases (p=0.0003). Simi-
lar correlations of nm23 expression in melanoma have
been confirmed by Florenes et al. [32], Lee et al. [30]
and others [33]. Not all authors, e.g. van den Oord et al.
[35], Easty et al. [36], Saitoh et al. [37] and Holmes et
al. [38] have detected the correlation of nm23 expression
in melanoma with survival time and metastases forma-
tion. Many authors performed the assessment of nm23
expression in other types of human cancer. Reduced le-
vels of nm23 protein and correlation with survival time
were detected in ductal breast cancer with regional lym-
phatic metastases [39]. In colon cancer there was a corre-
lation between a reduced level of of nm23 and the oc-
currence of metastases to liver, however no dependence
on the condition of regional lymphatic nodes was shown
[40].
In the group of patients we examined the detection
of nm23 expression in melanoma cells had some influ-
ence on prolonging survival time. The positive influence
of nm23 protein expression on survival time in the exami-
ned group is consistent with literature data [30-34].
Van den Oord et al. [35] emphasize that demonstra-
tion of nm23 by routine immunohistochemical methods
should not be the basis of the assessment of survival pro-
gnosis and postulate that only exact quantitative immuno-
histochemical methods can be the basis of such estimates.
During the course of the study it became impossible
to assess nm23 for 5 patients (13.9%). The assessment
of the remaining patients involved a comparison with he-
matoxyline/eosin – stained specimens. Only positive and
negative reactions were assessed.
The immunohistochemical analysis confirmed the
diagnostic value of HMB45 marker, however it did not
have any prognostic value because as it presents an almost
100% specificity for melanoma.
The analysis of histopathological factors in the exa-
mined group of patients has shown an unfavourable in-
fluence of lymphatic metastases on survival time at the be-
ginning of treatment. The research on the significance
of lymphatic node status in melanoma has, in the recent
years, led to changes in surgical treatment by introdu-
cing the SLN (Sentinel Lymph Node) biopsy. This me-
thod provides the possibility of verifing lymphatic node
condition as a significant prognostic factor. It also allows
to apply surgical treatment designed to spare lymphatic
nodes and to detect early micrometastases within lym-
Figure 7. Graph of cumulative proportion surviving by nm23 group
(Kaplan Meier – p=0.00076).
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phnodes. SLN procedures have improved treatment re-
sults and the patients' quality of life [3-6].
The depth of invasion in mm according to Breslow
and the level of invasion according to Clark, the most
often emphasized prognostic factors, did not have any
influence on survival in the analysed material. The signi-
ficance of histological type of melanoma with surface ty-
pe SSMM having better prognosis, preexisting naevus,
ulceration and lymphatic infiltration was not demonstra-
ted, either.
Within the group of clinical parameters (of which
age, male gender, melanoma anatomical location on the
trunk, shoulder girdle, neck or head are most often consi-
dered as unfavourable) none of them displayed any si-
gnificant influence on survival time in the examined gro-
up. The influence of PCNA, MMP-2 and CD44 on su-
rvival time was not determined.
Immunohistochemical methods are the basic tool in
the diagnosis and differentiation of pigment changes.
This research has provided evidence as to the prognostic
value of nm23 diphosphate nucleoside kinase in skin me-
lanoma.
Conclusions
1. The expression of nm23 diphosphate nucleoside kina-
se has displayed statistically significant correlation with
survival time in a group of patients with skin melano-
ma.
2. Despite the fact that the correlation between nm23
diphosphate nucleoside kinase and survival time has
been proven, no statistical correlation between nm23
expression and the occurrence of distant metastases
was detected.
3. The prognostic significance of the lymphatic metasta-
ses at the beginning of treatment was demonstrated
in the group of pathological factors.
Witold Kycler M.D.
2nd Department of Oncological Surgery
Greatpoland Cancer Centre in Poznaƒ
Garbary 15
61-866 Poznaƒ, Poland
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